Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Finding out you have cancer is hard, but telling the ones you love can be even harder.
Abstract. Improved cancer screening and treatment programs have led to an increased survivorship of patients with cancer, but consequently also to the rise in number…
Abstract. Nearly all glioblastoma (GBM) patients relapse following standard treatment and eventually succumb to disease. While large-scale, integrated multiomic studies have tremendously advanced the understanding…
There are increasingly more bladder-sparing strategies for patients with even aggressive bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer…
AI chatbots can outperform oncologists when answering patient questions about cancer, a new study suggests.
The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.
Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.
FDA and the European Medicines Agency granted an Orphan Drug Designation to Carthera for the use of carboplatin when used with SonoCloud technology in the…
Nazli Dizman, MD, discusses her research on adherence to the American Society of Clinical Oncology Language of Respect Guidelines among patients with renal cell carcinoma.